| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.6 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.6 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | -0.092 | 0.6 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |